The Challenge
Overview
When Amendola met Biofourmis, they were a small Singapore start-up about to announce their Series B and a move of their headquarters to Boston. While the AI-based virtual care and digital therapeutics company was known to Asia media, Amendola had a big—and exciting—job ahead of us to build and elevate their thought leadership/PR, high-value content, and social media program to ensure the company’s amazing story got told in a powerful way in the U.S. market.
Results
Amendola quickly became a valued extension of Biofourmis’ internal marketing team, working closely with them to build an integrated program. Amendola has created and executed a robust thought leadership program focused on digital therapeutics, decentralized clinical trials, care-at-home/virtual care, remote patient monitoring, artificial intelligence and machine learning.
Working closely with top-tier national and trade journalists, our work elevated Biofourmis founder Kuldeep Singh Rajput from a thought leader who was a relative unknown in the U.S. market to a media darling. We also have secured extensive coverage for the rest of the company’s C-Suite and its subject matter experts. We’ve secured hundreds of high-value articles and broadcast interviews—both thought leadership and breaking news.
Through a strategic approach, we’ve increased Biofourmis’ LinkedIn followers to more than 28,000. We’ve written awards applications that secured the company top honors such as Forbes’ Top 50 Most Promising AI Companies in America, Fierce Healthcare Innovation Awards Most Promising Innovation, CB Insights Most Promising Digital Health Start-Ups (x2), UCSF Digital Health Awards Best in Class Winner, Fierce Life Sciences Innovation Awards Top Digital Health Solution, PharmaVoice 100 for Rajput, and many more.
In 2022, Biofourmis announced its Series D round, propelling the company to health tech unicorn status with a $1.3 billion valuation. And now, everyone knows who Biofourmis is.
If there’s anyone who’s an extention of our internal team, it’s Amendola!